Exopert
2 known investors
Korean startup developing exosome isolation and Raman-based analysis technology for cancer diagnostics.
Also known as EXoPERT
Investors · 2
Company profile
researched Aug 2026EXoPERT is a South Korea-based startup working on exosome-based cancer diagnostics. Exosomes are small particles circulating in the body that carry DNA and protein information from their cells of origin, and the company's approach centers on recovering them from blood at high purity so they can be used as a diagnostic sample. EXoPERT uses chromatography to isolate exosomes without damaging them, then applies Raman scattering spectroscopy to characterize the isolated material, since shifts in scattered light reflect molecular vibration and rotation and therefore reveal molecular structure.
Because exosomes are complex biological assemblies containing many proteins and nucleic acids, the resulting Raman signals are difficult to interpret directly. EXoPERT applies deep learning to analyze these signals and to estimate similarity between a patient sample and cancer profiles. The company has described the method as simple, repeatable and free of radiation exposure, and expects applications beyond initial cancer detection, including assessment of cancer progression and prediction of postoperative course.
Latest developments
A March 2026 accelerator survey lists EXoPERT as an addition to the Johnson & Johnson Innovation JLABS incubator program in November 2025. JLABS operates on a no-equity basis with rolling admission and month-to-month agreements.
▸Full profile — technology, go-to-market, geography
Technology
The platform combines chromatographic isolation of high-purity, undamaged exosomes from blood with Raman scattering analysis of the isolated vesicles, and deep-learning models that interpret the resulting spectral signals to predict similarity between a patient sample and cancer. The company positions the workflow as repeatable and not requiring radiation.
Go-to-market
Early international exposure has come through government-supported startup programs and trade events, including a KISED-supported delegation to GITEX Technology Week in Dubai, and participation in Johnson & Johnson Innovation's JLABS incubator program, an equity-free life sciences incubator network with locations in Korea and elsewhere.
Cancer diagnostics, including detection, monitoring of disease progression and prediction of postoperative outcomes.
Geography
Headquartered in South Korea; the team exhibited internationally at GITEX Technology Week in Dubai in October 2019 with support from the Korea Institute of Startups & Entrepreneurship Development (KISED).
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 2
launches, deals, and filingsAn accelerator review lists EXoPERT as entering Johnson & Johnson Innovation - JLABS via its incubator program in November 2025; JLABS provides facilities and network access without taking equity.
EXoPERT's team attended GITEX Technology Week in Dubai, held October 6-10, 2019, as part of a delegation supported by the Korea Institute of Startups & Entrepreneurship Development (KISED).
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Korean startup EXoPERT develops exosome-based cancer diagnostic technology - Exosome RNAexosome-rna.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Exopert do?
- Korean startup developing exosome isolation and Raman-based analysis technology for cancer diagnostics.
- Who are Exopert's investors?
- Exopert's investors include Atinum Investment Co. Ltd., We Ventures.